The Valais-based start-up GaDia launches an innovative test to detect, in only 15 minutes, carbapenem-resistant bacteria. A fast and precise solution that could bring about a major change to hospital and private laboratories.
Based in BioArk Monthey, GaDia keeps innovating in the field of rapid diagnostic tests. Its latest product enables the identification of five types of carbapenemases, enzymes produced by antimicrobial-resistant bacteria. The latter are classified as an urgent threat by global health authorities.
Faced with the augmentation of resistant bacteria, traditional methods of diagnostics, long and expensive, have their limits. “Our test reduces the analysis duration to 15 minutes, compared to many hours, or even days when using traditional methods”, explains the founder of GaDia, Percevent Ducrest. Based on the lateral flow assay technology (similar to Covid tests), it achieves a level of precision ranging from 94 to 100%.
Addressed to hospital and private laboratories, this test answers a growing need. “The number of invitations to tender is multiplying itself in Europe, because hospitals are looking for reliable and cost-effective solutions,” he adds.
A niche strategy
GaDia stands out by positioning itself in specific markets, away from intense competition. “We do not create mainstream tests, but we target market sectors where expertise prevails,” highlights Percevent Ducrest.
Entirely produced in Valais, these tests boast a competitive price despite their quality. “The whole value chain is mastered locally. We even collaborate with students and retirees to strengthen our team”, he points out.
Prospects and recognition
Several invitations to tender gained in Europe confirm the test potential. “We have agreements ranging from 100 tests up to 100,000 over six years”, the founder explains. These achievements enable GaDia to consider further recruitment and investment, especially in European IVDR certification.
This project also proves the resilience of the start-up. “It has not been easy every day, but today, we prove that hard work pays off”, concludes Percevent Ducrest, grateful for its partners such as The Ark and CimArk.
With this new test, GaDia reinforces its position as an innovative player in the Valais healthcare sector… and well beyond.
More information: GaDia
Pictures: GaDia